CMS final rule on Medicare Advantage and Part D drug prices
The Centers for Medicare & Medicaid Services May 16 released a with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs. The rule finalizes language aimed at increasing transparency for Part D beneficiaries, as well as the option for MA plans to utilize step therapy for Part B drugs.
Related News Articles
Headline
The AHA April 30 released a report highlighting how hospitals and health systems continue to experience significant financial headwinds that can challenge…
News
The Centers for Medicare & Medicaid Services April 7 released finalized payment rates for calendar year 2026 Medicare Advantage and Part D plans. Payments…
Headline
The Centers for Medicare & Medicaid Services April 4 finalized changes to the Medicare Advantage and prescription drug programs for contract year 2026. The…
Headline
The AHA March 11 shared ways Congress could better support patient access to post-acute care in comments for a hearing held by the House Committee on Ways and…
Headline
A new AHA report highlights how certain practices by Medicare Advantage plans are increasing rural hospitals' vulnerabilities and threatening access to care in…
Headline
An analysis by KFF released Jan. 28 found that Medicare Advantage insurers made nearly 50 million prior authorization determinations in 2023. The finding…